FeesSafety
Pluang+

New preclinical data shows PRP can reprogram chemo-resistant pancreatic cancer cells to improve treatment response.

Market News
16 Oct 2026, 15:36 WIB
GlobeNewsWire
View Source
Bullish
New preclinical data shows PRP can reprogram chemo-resistant pancreatic cancer cells to improve treatment response.

Propanc Biopharma announced preclinical research revealing that its pancreatic proenzyme formulation, PRP, can remodel chemotherapy-resistant pancreatic cancer cells, making them more vulnerable to subsequent chemotherapy. The study demonstrated that PRP treatment reduces cancer cell proliferation, suppresses metastatic behavior, reverses cellular plasticity linked to resistance, and induces apoptosis. These findings support PRP's potential as a resistance-modulating therapy to be tested in a Phase 1b clinical trial starting Q1 2027, aiming to improve outcomes for patients with advanced solid tumors by overcoming treatment resistance.

Propanc Biopharma's lead asset PRP is the subject, with Pluang's Health-sector market data providing context. As of Oct 16, 2026 19:01 WIB, 93 of 150 priced Health-sector US stocks rose while 46 fell. Amneal Pharmaceuticals Inc. Class A Common Stock (AMRX) traded at USD 19.50 with a 1-day change of +1.30%, Canopy Growth Corp (CGC) was priced at USD 0.74 with Pluang order activity showing 100% Sell, and Tilray Brands Inc (TLRY) traded at USD 3.25 with 97% Sell activity.

More News

Goldman Sachs forecasts S&P 500 to rise 26% to 8,700 by late 2027 amid tech stock value rebound.

Goldman Sachs forecasts S&P 500 to rise 26% to 8,700 by late 2027 amid tech stock value rebound.

Goldman Sachs predicts the S&P 500 will climb about 26% to 8,700 points within the next 12 months, despite recent market volatility and concerns over AI-driven tech investments. The forecast is supported by lower valuations in tech stocks and a forwa...

Bullish
1 hour ago
S&P 500 nearly quadrupled investments in 10 years despite recent pullbacks, driven by rising corporate profits.

S&P 500 nearly quadrupled investments in 10 years despite recent pullbacks, driven by rising corporate profits.

Over the past decade, the S&P 500 index has risen 229%, turning a $1,000 investment into nearly $4,000, mainly due to a 212% increase in corporate earnings rather than valuation changes. Despite recent market drops and volatility, holding through pul...

Bullish
1 hour ago
Bristol Myers Squibb offers a 4.3% yield with strong new drug growth despite upcoming patent risks.

Bristol Myers Squibb offers a 4.3% yield with strong new drug growth despite upcoming patent risks.

Bristol Myers Squibb, a major pharmaceutical company, currently offers a 4.3% dividend yield and trades at a price-to-earnings ratio well below the industry average. Its newer drug portfolio generated nearly $7.7 billion in revenue last quarter, grow...

Market News
Bullish
1 hour ago
Nvidia stock plunges 43% after CEO Jensen Huang resigns amid scandal, but analyst sees 65% upside ahead.

Nvidia stock plunges 43% after CEO Jensen Huang resigns amid scandal, but analyst sees 65% upside ahead.

Nvidia's stock has dropped about 43% following CEO Jensen Huang's sudden resignation linked to alleged Chinese intelligence ties, wiping out over $2.5 trillion in market value. Despite concerns about leadership loss, analyst Dan Ives believes Nvidia'...

Market News
Bearish
1 hour ago
ASUS launches holiday sale with up to 44% off laptops and desktops until Dec 2, 2026

ASUS launches holiday sale with up to 44% off laptops and desktops until Dec 2, 2026

ASUS has announced a holiday sale offering discounts up to 44% on a wide range of laptops and desktops, available online and in stores like Best Buy until December 2, 2026. The sale features budget-friendly options like the ASUS Vivobook 14 starting ...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App